Rare EGFR mutations in lung adenocarcinoma

(5:34)

Dr. West on FDA Approval of Afatinib in NSCLC With Rare EGFR Mutations

(1:47)

Osimertinib For Uncommon EGFR Mutations in NSCLC

(3:30)

Activity of EGFR TKIs in patients with NSCLC with uncommon EGFR mutations

(2:45)

Afatinib in Patients With Uncommon EGFR Mutations

(4:6)

Testing for Common and Uncommon EGFR Mutations to Guide EGFR-Targeted Therapy in NSCLC

(41:59)

GRACEcastUC-020_Lung_Case in Point: How Should We Approach Someone with a Rare EGFR Mutation?

(6:3)

Afatinib Therapy for Uncommon EGFR Alterations in NSCLC

(3:47)

NGS provides improved identification of uncommon EGFR mutations over PCR in NSCLC

(1:4)

How to Understand EGFR T790M Mutations | Dana-Farber Cancer Institute

(4:25)

GRACE Targeted Therapies Lung Cancer 2021 - Management of Uncommon EGFR Mutations Including EXON 20

(22:49)

CRSF 07th Masterclass: Uncommon EGFR Mutations in Lung Cancer | Dr. Pradeep Ventrapati

(9:35)

Ask the Experts: Clinical Trials within Uncommon EGFR Alterations in NSCLC

(49:58)

Does the Specific EGFR Mutation Matter When Choosing an Oral EGFR Inhibitor?

(3:15)

EGFR Mutations: Uncommon Treatment \u0026 Insurance Complications -2022 Program: Targeted Therapies Forum

(4:9)

A New Treatment Option for Uncommon EGFR Mutations (BMIC-023)

(6:36)

Individual Treatments for Individual EGFR Mutations

(17:45)

Understanding NSCLC Treatment When You Have an EGFR Mutation

(5:3)

Treating Uncommon EGFR NSCLC Mutations with Osimertinib

(2:8)

Panel Discussion | Dr Vijay Patil | Management of Uncommon EGFR Mutations

(28:14)